William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given ...

ALLO Fiber has kicked off the return of ALLO for Education, a program where they support local schools throughout their fiberhoods. The program's success in the past has been a benefit to their ...

A formal ceremony took place today following the start of construction on Joplin’s new fiber-optic network. A groundbreaking ...

Allogene Therapeutics Inc (ALLO) reports a strong cash position and promising clinical progress, despite facing competitive ...

A groundbreaking in Joplin celebrates what officials hope will be a step towards a more connected city. City leaders joined ...

A new ISP is beginning construction in Joplin and an upcoming groundbreaking will welcome the company to the city. ALLO’s ...

On Wednesday, Allogene Therapeutics Inc (ALLO) stock saw a modest uptick, ending the day at $3.22 which represents a slight increase of $0.23 or 7.69% from the prior close of $2.99. The stock opened ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $4.50. The company’s shares closed last Friday at $3 ...

Construction has officially begun on ALLO’s state-of-the-art, 100% fiber-optic network in Joplin as of November 4.

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...

BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can ...